← Back to Search

Behavioural Intervention

Personalized Feedback for Cancer Survivor Physical Activity (Project KNOWN Trial)

N/A
Recruiting
Led By Yue Liao, MPH, PhD
Research Sponsored by The University of Texas at Arlington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 3 months.
Awards & highlights

Summary

This trial is looking at how to get cancer survivors who are at high risk for type 2 diabetes to be more physically active using personalized feedback.

Who is the study for?
This trial is for cancer survivors over 18, who've finished treatment at least 3 months ago and are at high risk for type 2 diabetes due to inactivity. Participants must speak English, have a smartphone with internet, and be able to exercise moderately without supervision. Those on certain insulin treatments, other health programs, incompatible smartphones, pregnant women, dialysis patients, overnight workers or those with activity-limiting health issues can't join.Check my eligibility
What is being tested?
The study tests if real-time glucose feedback from wearable devices motivates physical activity in inactive cancer survivors at risk of type 2 diabetes. It compares standard feedback against glucose-based biofeedback using continuous monitors and tracks daily activity levels to see the immediate effects of exercise on biological status.See study design
What are the potential side effects?
Since this trial involves non-invasive monitoring through wearables rather than medication or invasive procedures, significant side effects are not expected. However, participants may experience discomfort or skin irritation from wearing the devices.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 3 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 3 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of delivering personalized glucose-based feedback
Secondary outcome measures
Changes in daily physical activity level

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Biofeedback GroupExperimental Treatment1 Intervention
Group II: Standard Care GroupActive Control1 Intervention

Find a Location

Who is running the clinical trial?

The University of Texas at ArlingtonLead Sponsor
43 Previous Clinical Trials
4,829 Total Patients Enrolled
American Institute for Cancer ResearchOTHER
10 Previous Clinical Trials
8,511 Total Patients Enrolled
Yue Liao, MPH, PhDPrincipal InvestigatorUniversity of Texas at Arlington

Media Library

Glucose-based biofeedback (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05490641 — N/A
Cancer Research Study Groups: Biofeedback Group, Standard Care Group
Cancer Clinical Trial 2023: Glucose-based biofeedback Highlights & Side Effects. Trial Name: NCT05490641 — N/A
Glucose-based biofeedback (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05490641 — N/A
~10 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top